Summary Safety Review - ZOFRAN (ondansetron) - Assessing the Potential Harm to the Fetus
Health Canada carried out a safety review to assess the risk of birth defects with the use of ondansetron, as part of routine health product monitoring and because this drug is not authorized for sale in Canada to treat nausea and vomiting during pregnancy. The use of ondansetron during pregnancy is not recommended because its safety has not been established in pregnant women.
- Publisher - Current Organization Name: Health Canada
- Licence: Open Government Licence - Canada
Data and Resources
-
Summary Safety Review - ZOFRAN (ondansetron) - Assessing the Potential Harm to the FetusHTMLEnglish publication HTML
-
Summary Safety Review - ZOFRAN (ondansetron) - Assessing the Potential Harm to the FetusHTMLFrench publication HTML
Similar records